Holen Sie sich die Stockscreener-App
15.34
0.13%
0.1292
Schlusskurs vom Vortag:
$15.47
Offen:
$15.48
24-Stunden-Volumen:
14,720
Relative Volume:
0.01
Marktkapitalisierung:
$1.70B
Einnahmen:
$-249.00K
Nettoeinkommen (Verlust:
$-187.60M
KGV:
-6.1363
EPS:
-2.5
Netto-Cashflow:
$-201.88M
1W Leistung:
-8.45%
1M Leistung:
+25.63%
6M Leistung:
+93.87%
1J Leistung:
+348.99%
1-Tages-Spanne:
$15.36
$15.70
1-Wochen-Bereich:
$14.85
$17.49
52-Wochen-Spanne:
$2.865
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.44 | 1.70B | -249.00K | -187.60M | -201.88M | -2.50 |
|
ZTS
Zoetis Inc
|
124.22 | 55.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 53.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.30 | 46.40B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 37.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
472.38 | 20.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Trend Report: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesWeekly Trade Recap & Community Trade Idea Sharing - baoquankhu1.vn
Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX) - Seeking Alpha
FY2030 Earnings Estimate for AMLX Issued By HC Wainwright - MarketBeat
Is Amylyx Pharmaceuticals Inc still a buy after recent gainsJuly 2025 Chart Watch & Entry Point Strategy Guides - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amylyx nominates AMX0318 as long-acting GLP-1 candidate for rare endocrine disorders - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4.5%What's Next? - MarketBeat
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside - Yahoo Finance
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 By Investing.com - Investing.com Nigeria
Amylyx Pharma Hits New HighDelivers Over 160% Gain In 7 Months - Nasdaq
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighTime to Buy? - MarketBeat
January 2027 Options Now Available For Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 - Investing.com
Amylyx Pharmaceuticals (AMLX) Valuation After AMX0318 Rare Disease Pipeline Update - simplywall.st
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com Australia
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock By Investing.com - Investing.com India
Amylyx pharma co-CEO Cohen sells $1.87m in shares By Investing.com - Investing.com India
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $1,850,862.87 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $27,300.42 in Stock - MarketBeat
Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading 11.7% HigherHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 8.85% on Jan 20 - GuruFocus
EV Market: Is Amylyx Pharmaceuticals Inc stock a good pick for beginnersWeekly Stock Recap & Pattern Based Trade Signal System - baoquankhu1.vn
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders - Finviz
More Money In The Bank For Amylyx Pharmaceuticals Insiders Who Divested US$2.0m - 富途牛牛
Amylyx Pharmaceuticals Inc (AMLX) Trading 3.18% Higher on Jan 16 - GuruFocus
9 Overlooked Growth Stocks to Buy - Insider Monkey
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5%What's Next? - MarketBeat
Insider Trends: Will Amylyx Pharmaceuticals Inc. stock sustain high P E ratios2025 Trading Recap & Fast Moving Stock Watchlists - Bộ Nội Vụ
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) announces the selection of AMX0318 as development candidate for PBH and other rare diseases - MSN
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Finviz
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuation2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside - TipRanks
How Amylyx Pharmaceuticals’ (AMLX) Move Into GLP-1 Rare Diseases Has Changed Its Investment Story - Sahm
Amylyx selects AMX-0318 as development candidate - BioWorld MedTech
Amylyx selects AMX0318 as development candidate for PBH - Yahoo Finance
Is Amylyx Pharmaceuticals Inc. stock recession proofJuly 2025 Reactions & Stepwise Entry/Exit Trade Alerts - Улправда
Why Amylyx Pharmaceuticals Inc. stock could outperform in 2025Treasury Yields & Community Consensus Stock Picks - Улправда
Top Amylyx Executives Quietly Cash Out in Coordinated Stock Moves - TipRanks
James Frates Sells 3,326 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program By Investing.com - Investing.com Nigeria
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program - Investing.com Australia
US company unveils candidate for Gubra partnership - medwatch.com
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.55%
2.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):